{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:19:29Z","timestamp":1783383569405,"version":"3.54.6"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.1093\/ibd\/izag063","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:48:18Z","timestamp":1774529298000},"page":"1421-1422","source":"Crossref","is-referenced-by-count":0,"title":["Silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5225-0779","authenticated-orcid":false,"given":"Catarina","family":"Costa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Unidade Local de Sa\u00fade Gaia e Espinho , Vila Nova de Gaia,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-0139","authenticated-orcid":false,"given":"Maria Manuela","family":"Estevinho","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Unidade Local de Sa\u00fade Gaia e Espinho , Vila Nova de Gaia,","place":["Portugal"]},{"name":"Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto , Porto,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"2026070620123556500_izag063-B1","doi-asserted-by":"publisher","first-page":"e0175099","DOI":"10.1371\/journal.pone.0175099","article-title":"Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn\u2019s disease in the United States","volume":"12","author":"Patel","year":"2017","journal-title":"PLoS One"},{"key":"2026070620123556500_izag063-B2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00384-023-04397-7","article-title":"Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany","volume":"38","author":"Bokemeyer","year":"2023","journal-title":"Int J Colorectal Dis"},{"key":"2026070620123556500_izag063-B3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/apt.16723","article-title":"Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases\u2014a Danish nationwide cohort study","volume":"55","author":"Zhao","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620123556500_izag063-B4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5217\/ir.2024.00119","article-title":"Clinical characteristics of patients with difficult-to-treat ulcerative colitis: a nested case-control study using a Japanese claims database","volume":"24","author":"Matsuoka","year":"2026","journal-title":"Intest Res"},{"key":"2026070620123556500_izag063-B5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/s0092-8674(00)80240-8","article-title":"The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells","volume":"89","author":"Zheng","year":"1997","journal-title":"Cell"},{"key":"2026070620123556500_izag063-B6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1538\/expanim.63.133","article-title":"Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis","volume":"63","author":"Okamura","year":"2014","journal-title":"Exp Anim"},{"key":"2026070620123556500_izag063-B7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.gastro.2016.09.005","article-title":"Rectal delivery of a DNAzyme that specifically blocks the transcription factor GATA3 and reduces colitis in mice","volume":"152","author":"Popp","year":"2017","journal-title":"Gastroenterology"},{"key":"2026070620123556500_izag063-B8","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izag046","article-title":"Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial","author":"Atreya","year":"2026"},{"key":"2026070620123556500_izag063-B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12876-025-03603-w","article-title":"Correlation and diagnostic significance of CD4 T cell subsets and NLRP3 inflammasome in ulcerative colitis: the role of the NLRP3\/T-bet\/GATA3 axis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"2026070620123556500_izag063-B10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3748\/wjg.v30.i6.527","article-title":"Emerging role of exosomes in ulcerative colitis: Targeting NOD-like receptor family pyrin domain containing 3 inflammasome","volume":"30","author":"Li","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2026070620123556500_izag063-B11","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1002\/ctm2.1471","article-title":"A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis","volume":"13","author":"Klughammer","year":"2023","journal-title":"Clin Transl Med"},{"key":"2026070620123556500_izag063-B12","author":"Sanofi-Aventis Research and Development"},{"key":"2026070620123556500_izag063-B13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070620123556500_izag063-B14","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1053\/j.gastro.2025.01.128","article-title":"vedolizumab plus curcumin-qingdai for patients with ulcerative colitis","volume":"168","author":"Peterka","year":"2025","journal-title":"Gastroenterology"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1421\/68022956\/izag063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1421\/68022956\/izag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:12:41Z","timestamp":1783383161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/7\/1421\/8650909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4,10]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag063","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,10]]}}}